Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, March 9, 2023
Eisai Certified as a 2023 Health and Productivity Management Outstanding
Monday, March 6, 2023
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Thursday, March 2, 2023
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan
Tuesday, February 28, 2023
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Tuesday, February 21, 2023
Dissolution of Bracco-Eisai Joint Venture
Monday, January 30, 2023
Lecanemab Receives Priority Review Status in Japan
Friday, January 27, 2023
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
Thursday, January 19, 2023
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company
Wednesday, January 18, 2023
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: